Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs
Affiliate disclosure: we earn commission from some partners. Learn more.

Statins (HMG-CoA reductase inhibitors)

Target: HMG-CoA reductase (cholesterol biosynthesis pathway)

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Last verified by WeighedHealth Editorial Team against primary sources
0-55%
LDL-C reduction across intensities
~0%
relative MACE reduction per 1 mmol/L LDL drop
~0%
muscle-symptom rate (placebo-controlled blinded analyses)
$0-15/mo
generic cash price floor

What are statins (hmg-coa reductase inhibitors)?

Statins are the cornerstone of pharmacologic LDL-cholesterol lowering and the most widely prescribed cardiovascular drug class in the world. They inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which upregulates LDL receptor expression and clears LDL from circulation. The seven approved statins differ in potency (high-intensity vs moderate-intensity), pharmacokinetics, and drug-interaction footprint.

How do statins (hmg-coa reductase inhibitors) work?

By blocking HMG-CoA reductase in hepatocytes, statins reduce intracellular cholesterol pool. The liver compensates by upregulating LDL receptors on its surface, pulling more LDL-C out of plasma. Typical LDL reductions: 30-55% with high-intensity (rosuvastatin 20-40 mg, atorvastatin 40-80 mg) and 25-35% with moderate-intensity (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg). Beyond LDL, statins have pleiotropic anti-inflammatory effects on the arterial wall that may explain part of their cardiovascular benefit.

History of statins (hmg-coa reductase inhibitors)

Lovastatin (Mevacor, 1987) was the first commercial statin, isolated from Aspergillus terreus by Merck's Akira Endo collaboration. Simvastatin (Zocor, 1991), pravastatin (Pravachol, 1991), and fluvastatin (Lescol, 1993) followed. Atorvastatin (Lipitor, 1996) became the best-selling drug in history with ~$125B lifetime sales before losing patent. Rosuvastatin (Crestor, 2003) is the most potent. Pitavastatin (Livalo, 2009) is the newest. All except pitavastatin are now generic and cost $4-15/month.

Drugs in this class

    Other drug classes

    Related topics

    Sources

    Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.

    1. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol · Journal of the American College of Cardiology, 2019 · PMID 30586774
    2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants · The Lancet (Cholesterol Treatment Trialists' Collaboration), 2010 · PMID 21067804
    3. Adverse effects of statin therapy: perception vs. the evidence · European Heart Journal, 2018 · PMID 29718253
    4. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON) · New England Journal of Medicine, 2020 · PMID 33196154

    People also ask

    • Are statin muscle side effects real?

      Yes and no. Open-label studies report 5-29% muscle symptoms; blinded placebo-controlled trials (SAMSON, StatinWISE) show that the majority of these symptoms occur on placebo too — i.e., true statin-specific muscle effect is closer to 1-5%. The nocebo effect is real and large. Rhabdomyolysis is rare (<0.1%) but serious. The pragmatic approach: try a different statin and a lower dose before concluding intolerance.

    • Do statins cause diabetes?

      There is a small but real increase in incident type 2 diabetes (~1 additional case per 200 patient-years on high-intensity therapy). The cardiovascular benefit substantially outweighs this risk in patients with elevated ASCVD risk. Patients with pre-diabetes should be monitored; the benefit calculus shifts in primary prevention with very low baseline cardiovascular risk.

    • Which statin has the fewest side effects?

      Pravastatin and rosuvastatin are hydrophilic and have lower muscle-symptom rates than lipophilic statins (simvastatin, atorvastatin, lovastatin). Pravastatin has minimal CYP3A4 interaction, making it the safest with many drug combinations. Pitavastatin is also low-interaction but expensive (still brand-only).

    • Can I take grapefruit juice with my statin?

      Avoid with simvastatin, lovastatin, and atorvastatin — grapefruit inhibits CYP3A4 and can raise blood levels 2-15x, increasing muscle-toxicity risk. Pravastatin, rosuvastatin, fluvastatin, and pitavastatin are not CYP3A4 substrates and are safe with grapefruit.

    • Do I need to take statins at night?

      Short-half-life statins (simvastatin, lovastatin, fluvastatin IR) should be taken in the evening, when hepatic cholesterol synthesis peaks. Long-half-life statins (atorvastatin, rosuvastatin, pitavastatin) work equally well taken any time of day — pick whichever is easier to remember.

    • Should I take CoQ10 with my statin?

      Mechanistic plausibility (statins reduce mitochondrial CoQ10 synthesis), but randomized trial evidence for symptomatic benefit is weak. No harm in trying; reasonable expectation: modest effect for a minority of patients. Don't substitute supplementation for genuine reassessment of muscle symptoms.

    Share: